國家衛生研究院 NHRI:Item 3990099045/8703
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 853959      Online Users : 1358
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/8703


    Title: EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82
    Authors: Yang, CH;Chou, HC;Fu, YN;Yeh, CL;Cheng, HW;Chang, IC;Liu, KJ;Chang, GC;Tsai, TF;Tsai, SF;Liu, HP;Wu, YC;Chen, YT;Huang, SF;Chen, YR
    Contributors: National Institute of Cancer Research;Institute of Molecular and Genomic Medicine
    Abstract: Epidermal growth factor receptor (EGFR) gene mutations are strongly associated with lung adenocarcinoma and favorable response to EGFR tyrosine kinase inhibitor. The mutated EGFR proteins (EGFRs) are hyper-phosphorylated and refractory to receptor down-regulation. To address the discrepancy between hyper-phosphorylation and lack of down-regulation of mutant EGFRs, we have examined the expression of EGFR negative regulators in non-small cell lung cancer (NSCLC) cell lines. We found that NSCLC cell lines expressing mutant EGFRs often had low expression of various negative regulators for EGFR. Among them, tumor suppressor CD82 was up-regulated by wild type (WT) EGFR but down-regulated by mutant EGFRs. Reconstitution of CD82 exerted stronger suppressive effects on mutant EGFRs than on WT EGFR. Active exportation of CD82 through exosome was one of the mechanisms involved in achieving the overall CD82 down-regulation in mutant EGFR-expressing lung cancer cell lines. Over-expression of mutant EGFR protein frequently occurred in the lung cancer tissues of mutant EGFR-transgenic mice and also associated with CD82 down-regulation. Immunoblot analyses on the tumor tissues from 23 lung adenocarcinoma patients (12 with WT EGFR, and 11 with mutant EGFRs) also identified significantly stronger down regulation of CD82 in tumors with mutant EGFRs than WT. Our data indicate that CD82 down-regulation could be a critical step involved in the EGFR over-expression and the stronger tumorigenic activity triggered by EGFR mutations. Up-regulation of the CD82 level may become a promising new treatment strategy for lung adenocarcinoma.
    Date: 2015-07
    Relation: Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2015 Jul;1852(7):1540-1549.
    Link to: http://dx.doi.org/10.1016/j.bbadis.2015.04.020
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0925-4439&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000355715200031
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84928601432
    Appears in Collections:[Ko-Jiunn Liu] Periodical Articles
    [Yi-Rong Chen] Periodical Articles
    [Shiu-Feng Kathy Huang] Periodical Articles
    [Shih-Feng Tsai] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    SDO092544391500126X.pdf1070KbAdobe PDF1073View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback